Page 5 - Catalent Zydis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Catalent zydis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Catalent Zydis Today - Breaking & Trending Today

Catalent Posts Wider-than-expected Q2 Loss; Revenues Down

Catalent, Inc. (CTLT) reported Friday that its second-quarter net loss was $204 million or $1.12 per share, compared to last year's net earnings of $81 million or $0. ....

Catalent Inc , Thomson Reuters , Atalent Earnings ,

Catalent Q2 sales inch past estimates amid takeover by Novo Holdings

The New Jersey-based firm is the main supplier of fill-finish work - involving filling and packaging syringes and injection pens in sterile conditions - for Novo's popular weight-loss drug, Wegovy. Catalent's shares were marginally higher at $56.70, compared with Novo's offer of $63.50 per share. "We've been surprised by the continued weakness," said Stephens analyst Jacob Johnson. ....

Bruxelles Capitale , United States , Pooja Desai , Bhanvi Satija , Sriparna Roy , Alessandro Maselli , Eli Lilly , Novo Holding , Novo Nordisk , Novo Holdings , Wall Street , Elliott Investment Management , New Jersey Based , Sarepta Therapeutics , Wall Street Estimates , Jacob Johnson , Sarepta Therapeutics , Eli Lilly , Ersey Based Firm ,

EU watchdog looking into impact on drug availability from Catalent-Novo deal

FRANKFURT (Reuters) -The European Union's drugs regulator said on Wednesday it will investigate any risks to the availability of medicines processed at Catalent sites that will be sold to Novo Nordisk, part of its mandate to prevent drug shortages. The European Medicines Agency told Reuters in a statement that its Medicine Shortages Single Point of Contact (SPOC) Working Party will liaise with member states to gather data on the products manufactured at the sites. Novo Nordisk on Monday moved to boost output of its popular obesity drug Wegovy as its parent holding struck a deal to buy Catalent, a key contract manufacturer of the product, for $16.5 billion. ....

United States , Bruxelles Capitale , Ludwig Burger , Eli Lilly , Anaz Ashkenazi , David Ricks , Kirsten Donovan , Novo Nordisk , European Union , European Medicines Agency , Medicine Shortages Single Point , Working Party , Financial Times , European Medicines Agency , Drug Shortages , European Union , Working Party ,